Serán Bioscience Takes Biospring Backing to Bridge Development and Commercial Supply

Serán Bioscience has raised an undisclosed growth investment led by Biospring Partners, adding a healthcare growth buyout firm with a pharmaceutical-services thesis to a cap table already anchored by Vivo Capital and Bain Capital Life Sciences. Both existing investors participated again, alongside members of Serán's executive leadership, according to the September 2026 announcement. The financing amount, valuation, ownership percentages and security terms were not disclosed.

The Bend, Oregon, company operates across formulation, particle engineering, analytical work and clinical manufacturing — the development-side services that sit upstream of commercial production. The new capital is meant to fund growth in that clinical business while financing Serán's transition into commercial-scale manufacturing, a move the company describes as carrying more operational risk than the phrase "capacity expansion" implies.

The centerpiece is a new multi-suite greenfield facility scheduled for completion in Q3 2027, part of an integrated Bend campus exceeding 200,000 square feet. It is designed for OEB4 manufacturing across oral, pulmonary and other drug-delivery formats, with announced capabilities including commercial-scale spray drying, nano-milling, granulation, tableting, coating, encapsulation and specialized dry-powder filling for immediate- and modified-release products. The facility is planned to connect with an adjacent packaging and logistics operation Serán says already provides validated packaging and labeling, unit-level serialization and global cold-chain distribution.

The commercial handoff is where the technical argument gets harder. Larger equipment can shift heat transfer, solvent removal, particle characteristics, powder flow and compression, while quality controls grow more demanding as programs move from small clinical batches toward repeatable commercial supply. Serán's pitch is that keeping formulation development, clinical manufacturing, commercial scale-up, finished-dose production, packaging and logistics with one partner can reduce the number of technical transfers and institutional handoffs surrounding a product — preserving process knowledge inside a single quality and operating system.

Biospring Partners describes itself as focused on pharmaceutical services, including outsourced manufacturing and clinical-trial services. Its lead role comes alongside two backers with longer histories at the company. Bain Capital's 2024 transaction committed more than $200M to Serán's growth and commercial-facility plan; Vivo Capital made a majority investment in January 2021, when Serán employed more than 50 people and was already planning a larger commercial manufacturing operation. The latest financing is separate from the 2024 amount, and Serán has not disclosed how much Biospring or the other participants committed.